Research and development of κ opioid receptor agonists and δ opioid receptor agonists

Hiroshi Nagase, Akiyoshi Saitoh

Research output: Contribution to journalReview article

Abstract

Delta opioid delta receptor (DOP) agonists were expected to be analgesics and many researchers tried to develop the SNC80 derivatives. However, the derivatives were dropped at the stage of early clinical trials because of undesirable side effects and weak analgesia. On the other hand, DOP agonists have been proposed as attractive candidates for the novel psychotropic drugs. We recently succeeded in synthesizing a novel selective DOP agonist KNT-127. KNT-127 produced neither catalepsy nor convulsive effects. We have demonstrated that KNT-127 has potent anxiolytic-like effect in rat models of innate anxiety. This anxiolytic-like effect was independent from known adverse effect of benzodiazepine, such as memory impairment, motor coordination deficits, and ethanol interactions. We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression. This antidepressant-like effect was independent from known adverse effect of selective serotonin reuptake inhibitor (SSRI), such as digestive symptoms. Therefore, we propose that DOP should be considered as an attractive target for the development of novel psychotropic drugs, without producing the adverse effects associated with benzodiazepine anxiolytics and SSRI antidepressants. Very recently, we developed another delta agonist NC-2800 with a different structure. NC-2800 is now in the preclinical stage using the CiCLE fund supported by AMED (Japanese Agency for Medical Research and Development).

Original languageEnglish
Article number107427
JournalPharmacology and Therapeutics
Volume205
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Opioid Receptors
Anti-Anxiety Agents
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Benzodiazepines
Research
Catalepsy
delta Opioid Receptor
Financial Management
Ataxia
Analgesia
Analgesics
Biomedical Research
Ethanol
Anxiety
Research Personnel
Clinical Trials
Depression
KNT 127

Keywords

  • Antidepressant
  • Anxiolytic
  • KNT-127
  • SNC80
  • TAN-67
  • δ-opioid agonists

Cite this

@article{103af9f03d7e436ea9c0aea9052573ea,
title = "Research and development of κ opioid receptor agonists and δ opioid receptor agonists",
abstract = "Delta opioid delta receptor (DOP) agonists were expected to be analgesics and many researchers tried to develop the SNC80 derivatives. However, the derivatives were dropped at the stage of early clinical trials because of undesirable side effects and weak analgesia. On the other hand, DOP agonists have been proposed as attractive candidates for the novel psychotropic drugs. We recently succeeded in synthesizing a novel selective DOP agonist KNT-127. KNT-127 produced neither catalepsy nor convulsive effects. We have demonstrated that KNT-127 has potent anxiolytic-like effect in rat models of innate anxiety. This anxiolytic-like effect was independent from known adverse effect of benzodiazepine, such as memory impairment, motor coordination deficits, and ethanol interactions. We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression. This antidepressant-like effect was independent from known adverse effect of selective serotonin reuptake inhibitor (SSRI), such as digestive symptoms. Therefore, we propose that DOP should be considered as an attractive target for the development of novel psychotropic drugs, without producing the adverse effects associated with benzodiazepine anxiolytics and SSRI antidepressants. Very recently, we developed another delta agonist NC-2800 with a different structure. NC-2800 is now in the preclinical stage using the CiCLE fund supported by AMED (Japanese Agency for Medical Research and Development).",
keywords = "Antidepressant, Anxiolytic, KNT-127, SNC80, TAN-67, δ-opioid agonists",
author = "Hiroshi Nagase and Akiyoshi Saitoh",
year = "2020",
month = "1",
doi = "10.1016/j.pharmthera.2019.107427",
language = "English",
volume = "205",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

Research and development of κ opioid receptor agonists and δ opioid receptor agonists. / Nagase, Hiroshi; Saitoh, Akiyoshi.

In: Pharmacology and Therapeutics, Vol. 205, 107427, 01.2020.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Research and development of κ opioid receptor agonists and δ opioid receptor agonists

AU - Nagase, Hiroshi

AU - Saitoh, Akiyoshi

PY - 2020/1

Y1 - 2020/1

N2 - Delta opioid delta receptor (DOP) agonists were expected to be analgesics and many researchers tried to develop the SNC80 derivatives. However, the derivatives were dropped at the stage of early clinical trials because of undesirable side effects and weak analgesia. On the other hand, DOP agonists have been proposed as attractive candidates for the novel psychotropic drugs. We recently succeeded in synthesizing a novel selective DOP agonist KNT-127. KNT-127 produced neither catalepsy nor convulsive effects. We have demonstrated that KNT-127 has potent anxiolytic-like effect in rat models of innate anxiety. This anxiolytic-like effect was independent from known adverse effect of benzodiazepine, such as memory impairment, motor coordination deficits, and ethanol interactions. We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression. This antidepressant-like effect was independent from known adverse effect of selective serotonin reuptake inhibitor (SSRI), such as digestive symptoms. Therefore, we propose that DOP should be considered as an attractive target for the development of novel psychotropic drugs, without producing the adverse effects associated with benzodiazepine anxiolytics and SSRI antidepressants. Very recently, we developed another delta agonist NC-2800 with a different structure. NC-2800 is now in the preclinical stage using the CiCLE fund supported by AMED (Japanese Agency for Medical Research and Development).

AB - Delta opioid delta receptor (DOP) agonists were expected to be analgesics and many researchers tried to develop the SNC80 derivatives. However, the derivatives were dropped at the stage of early clinical trials because of undesirable side effects and weak analgesia. On the other hand, DOP agonists have been proposed as attractive candidates for the novel psychotropic drugs. We recently succeeded in synthesizing a novel selective DOP agonist KNT-127. KNT-127 produced neither catalepsy nor convulsive effects. We have demonstrated that KNT-127 has potent anxiolytic-like effect in rat models of innate anxiety. This anxiolytic-like effect was independent from known adverse effect of benzodiazepine, such as memory impairment, motor coordination deficits, and ethanol interactions. We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression. This antidepressant-like effect was independent from known adverse effect of selective serotonin reuptake inhibitor (SSRI), such as digestive symptoms. Therefore, we propose that DOP should be considered as an attractive target for the development of novel psychotropic drugs, without producing the adverse effects associated with benzodiazepine anxiolytics and SSRI antidepressants. Very recently, we developed another delta agonist NC-2800 with a different structure. NC-2800 is now in the preclinical stage using the CiCLE fund supported by AMED (Japanese Agency for Medical Research and Development).

KW - Antidepressant

KW - Anxiolytic

KW - KNT-127

KW - SNC80

KW - TAN-67

KW - δ-opioid agonists

UR - http://www.scopus.com/inward/record.url?scp=85075361707&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2019.107427

DO - 10.1016/j.pharmthera.2019.107427

M3 - Review article

C2 - 31654658

AN - SCOPUS:85075361707

VL - 205

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

M1 - 107427

ER -